General index

GENERAL INTRODUCTION 1

1. MOLECULAR RECOGNITION 4

1.1. Sensors as an application of molecular recognition 7

1.2. Biosensors: Characteristics and classification 15

1.3. Current tendencies in biosensing 24

2. NANOTECHNOLOGY 25

3. ORGANIC-INORGANIC HYBRID POROUS MATERIALS 28

3.1. Types of porous materials 30

3.2. Porous anodic alumina (PAA) 31

3.3. Anodic alumina functionalization 33

4. GATED MATERIALS 41

5. IMPORTANCE OF GLOBAL INFECTIOUS DISEASE CONTROL 49

5.1. Vegetal-infecting pathogens 50

5.2. Animal-infecting pathogens 54

5.2.1. Pathogens and respiratory diseases 56

6. REFERENCES 59

OBJECTIVES 83

CHAPTER I | ADVANCEMENTS IN NANOMATERIAL-ENHANCED BIOSENSING FOR THE DETECTION OF *XYLELLA FASTIDIOSA* 87

1. ABSTRACT 90

2. INTRODUCTION 90

3. RESULTS AND DISCUSSION 96

3.1. Release assays *100*

3.2. Stability evaluation in blank and inoculated competitive media *102*

3.3. Sensitivity studies *103*

3.4. Study of the system behavior with different sub-species of Xylella fastidiosa *105*

3.5. Detection of Xylella fastidiosa in real field samples *106*

4. CONCLUSION 109

5. MATERIALS AND METHODS 110

5.1. General techniques *110*

5.2. Chemicals *110*

5.3. Oligonucleotides design *110*

5.4. Synthesis of support S_1 ..... *111*

5.5. Synthesis of support S_2 ..... *111*

5.6. Synthesis of support S_3 ..... *111*

5.7. Synthesis of support S_3-O_2 ..... *111*

5.8. Characterization of the prepared supports *112*

5.9. Release experiments of support S_3-O_2 ..... *112*

5.10. Plant extracts preparation *112*

5.11. Samples validation *113*

5.12. Statistical analysis *113*

6. REFERENCES 114

CHAPTER II | TARGETED DETECTION OF *MYCOBACTERIUM TUBERCULOSIS* USING AN ANTIBODY-COATED NANOPOROUS ANODIC ALUMINA BIOSENSOR FOR MPT64 ANTIGEN: A NOVEL APPROACH FOR TUBERCULOSIS SCREENING 121

1. ABSTRACT 124

2. INTRODUCTION 124

3. RESULTS AND DISCUSSION 131

3.1. Design, synthesis and characterization of gated NAA materials 131

3.2. Purified antigen-triggered cargo release 136

3.3. Specificity and sensitivity assays 136

3.4. Detection of M. tuberculosis in competitive media and clinical samples 139

4. CONCLUSIONS 144

5. MATERIALS AND METHODS 145

5.1. Reagents 145

5.2. Material characterization 146

5.3. Linker peptide design 146

5.4. ELISA peptides assay 146

5.5. Synthesis of solids 147

5.6. Cargo quantification 148

5.7. Detection protocol 148

5.8. Quantification curve of MPT64 protein recognition 149

5.9. Specificity 149

5.10. Validation in competitive media 150

5.11. MPT64 detection in patient samples 150

6. REFERENCES 151

CHAPTER III | APTAMER-CAPPED NANOPOROUS ANODIC ALUMINA FOR SARS-COV-2 SPIKE PROTEIN DETECTION 157

1. ABSTRACT 161

2. INTRODUCTION 161

3. RESULTS AND DISCUSSION 165

3.1. Synthesis and characterization of gated NAA 165

3.2. Release assays 168

3.3. Sensitivity and specificity studies 170

3.4. Detection of VSV-S in competitive media and inoculated clinical samples 173

3.5. Study of the system behavior with different S proteins from different SARS-CoV-2 variants of concern 175

4. CONCLUSION 176

5. MATERIALS AND METHODS 177

5.1. General Techniques 177

5.2. Reactives and reagents 177

5.3. Oligonucleotides Design 177

5.4. Synthesis of solids 177

5.5. Cargo quantification 178

5.6. Virus obtention 178

5.7. Detection protocol 179

5.8. Quantification curve of SARS-CoV-2 spike protein recognition 180

5.9. Selectivity 180

5.10. Validation in competitive media 180

5.11. Study of the system behavior with different VSV-S variants 181

6. REFERENCES 181

7. SUPPORTING INFORMATION 186

CHAPTER IV | NUCLEIC ACID DETECTION WITH GATED NANOPOROUS ANODIC ALUMINA AND CRISPR-CAS12A 191

1. ABSTRACT 194
2. INTRODUCTION 194
3. RESULTS AND DISCUSSION 198

3.1. Design, synthesis, and characterization of gated NAA materials 198

3.2. CRISPR-Cas12a regulation of cargo release 202

3.3. Specificity and sensitivity assays 207

3.4. Detection of SARS-CoV-2 in clinical samples 209

4. CONCLUSIONS 211
5. MATERIALS AND METHODS 212

5.1. Reagents 212

5.2. Material characterization 213

5.3. Material preparation for release assays 213

5.4. CRISPR-Cas12a-based detection 214

5.5. Patient samples 215

5.6. Nucleic acid amplification by RT-RP 215

5.7. SARS-CoV-2 detection in patient samples 215

5.8. RT-qPCR validation 216

6. REFERENCES 216
7. SUPPORTING INFORMATION 222

DISCUSSION 227

CONCLUSIONS 235